Aquinox to Present at Jefferies 2016 Healthcare Conference

VANCOUVER, British Columbia, June 01, 2016 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that Kamran Alam, Aquinox Vice President of Finance & CFO, will present a corporate overview at the upcoming Jefferies 2016 Healthcare Conference in New York city on Thursday, June 9th 2016 at 8:00 AM Eastern Time.

A live audio webcast and archive of the event will be available here.

To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.

About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox’s lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox plans to initiate a Phase 3 trial in 2016 with AQX-1125 for treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.

For more information, please visit www.aqxpharma.com.

Investor Contact Info:
Brendan Payne, Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
ir@aqxpharma.com

Gitanjali Ogawa, Vice President
The Trout Group
646-378-2949
Gogawa@troutgroup.com